

## Clinical Policy: Pralatrexate (Folotyn)

Reference Number: LA.PHAR.313

Effective Date: 11.04.23

Last Review Date: ~~11.20.25~~12.10.24

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**\*\*Please note: This policy is for medical benefit\*\***

### Description

Pralatrexate injection (Folotyn<sup>®</sup>) is a folate analog metabolic inhibitor.

### FDA Approved Indication(s)

Folotyn is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of Louisiana Healthcare Connections that pralatrexate and Folotyn are **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Peripheral T-Cell Lymphoma (must meet all):

1. Diagnosis of PTCL (*see Appendix D for examples of PTCL subtypes*);
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age  $\geq$  18 years;
4. One of the following (a or b):
  - a. Prescribed as initial palliative intent therapy;
  - b. Failure of at least one prior therapy (*see Appendix B for examples*);\*  
*\*Prior authorization may be required for prior therapies*
5. Prescribed as a single agent;
6. If request is for Folotyn, member must use pralatrexate, unless contraindicated or clinically significant adverse effects are experienced;
- 6-7. Request meets one of the following (a or b):\*
  - a. Dose does not exceed 30 mg/m<sup>2</sup> once weekly for 6 weeks in 7-week cycles;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).  
*\*Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: ~~12 months~~ **6 months**

Formatted: Font: Bold

Formatted: Don't keep with next

**B. NCCN-Recommended Off-Label Indications** (must meet all):

1. Diagnosis of one of the following (a or b):
  - a. Primary cutaneous ~~T-cell~~ lymphomas (i, ii, or ~~iii~~):
    - i. Mycosis fungoides or Sézary syndrome;
    - ii. Primary cutaneous anaplastic large cell lymphoma (ALCL) with multifocal lesions, or cutaneous ALCL with regional nodes;
    - iii. Subcutaneous panniculitis-like T-cell lymphoma with one of the following (1 or 2):
      - 1) Hemophagocytic lymphohistiocytosis, systemic disease, or high tumor burden;
      - 2) Inadequate response to first-line therapy (see Appendix B for examples);
  - b. Other T-cell lymphomas (i, ii, iii, or iv):
    - i. Adult T-cell leukemia/lymphoma (ATLL) after failure of first-line therapy (see Appendix B for examples);
    - ii. Extranodal NK/T-cell lymphoma (NKTL) following asparaginase-based therapy (see Appendix B for examples);
    - iii. Hepatosplenic T-cell lymphoma after failure of 2 prior treatment regimens (see Appendix B for examples);
    - iv. Breast implant (BI)-associated ALCL after failure of first-line therapy (see Appendix B for examples);
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age  $\geq$  18 years;
4. For diagnoses other than Mycosis fungoides or Sézary syndrome, prescribed as a single agent;
5. If request is for Folutyn, member must use pralatrexate, unless contraindicated or clinically significant adverse effects are experienced;

~~5-6.~~ Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).\*

\*Prescribed regimen must be FDA-approved or recommended by NCCN.

Formatted: Bullets and Numbering

Approval duration: ~~12 months~~ **6 months**

Formatted: Font: Bold

**C. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

Formatted: Indent: Left: 0.25", Hanging: 0.25", Keep with next

**II. Continued Therapy**

**CLINICAL POLICY**  
**Pralatrexate**



**A. All Indications in Section I (must meet all):**

1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Folutyn for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for Folutyn, member must use pralatrexate, unless contraindicated or clinically significant adverse effects are experienced;
- 3.4. If request is for a dose increase, request meets one of the following (a or b):\*
  - a. New dose does not exceed 30 mg/m<sup>2</sup> once weekly for 6 weeks in 7-week cycles;
  - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

\*Prescribed regimen must be FDA-approved or recommended by NCCN.

**Approval duration: 12 months**  
~~12 months~~

Formatted: Font: Bold

**B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy ~~for the relevant line of business-~~LA.PMN.53 ~~for Medicaid.~~

**III. Diagnoses/Indications for which coverage is NOT authorized**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – LA.PMN.53 ~~for Medicaid, or evidence of coverage documents.~~

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

ALCL: anaplastic large cell lymphoma	HGTL: hepatosplenic gamma-delta T-cell lymphoma
ATLL: adult T-cell leukemia/lymphoma	NCCN: National Comprehensive Cancer Network
BI-ALCL: breast implant-associated anaplastic large cell lymphoma	NKTL: extranodal NK/T-cell lymphoma
FDA: Food and Drug Administration	PTCL: peripheral T-cell lymphoma

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
PTCL - examples of first-line and subsequent therapy:	Varies	Varies

**CLINICAL POLICY**  
Pralatrexate



Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
<ul style="list-style-type: none"> <li>Brentuximab vedotin + CHP (cyclophosphamide, doxorubicin, and prednisone)</li> <li>CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone)</li> <li>CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)</li> <li>Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)</li> <li>DHAP (dexamethasone, cisplatin, cytarabine)</li> <li>ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin)</li> <li>Belinostat, brentuximab vedotin, romidepsin as single agents</li> </ul>		
<p>ATLL - examples of first-line therapy:</p> <ul style="list-style-type: none"> <li>Brentuximab vedotin + CHP (cyclophosphamide, doxorubicin, and prednisone)</li> <li>CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone)</li> <li>CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)</li> <li>Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)</li> <li>HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with high-dose methotrexate and cytarabine</li> </ul>	Varies	Varies
<p>NKTL - examples of asparaginase-based therapy:</p> <ul style="list-style-type: none"> <li>AspaMetDex (pegaspargase, methotrexate, dexamethasone)</li> <li>DDGP (dexamethasone, cisplatin, gemcitabine, pegaspargase)</li> <li>Modified-SMILE (steroid, methotrexate, ifosfamide, pegaspargase, etoposide)</li> <li>P-GEMOX (gemcitabine, pegaspargase, oxaliplatin)</li> </ul>	Varies	Varies
<p>Hepatosplenic T-cell lymphoma - examples of first-line therapy (for subsequent therapy examples see PTCL):</p> <ul style="list-style-type: none"> <li>ICE (ifosfamide, carboplatin, etoposide)</li> <li>CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone)</li> <li>Brentuximab vedotin + CHP (cyclophosphamide, doxorubicin, and prednisone)</li> </ul>	Varies	Varies
<p>BI-ALCL - examples of first-line therapy:</p> <ul style="list-style-type: none"> <li>Brentuximab vedotin</li> </ul>	Varies	Varies

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
<ul style="list-style-type: none"> <li>Brentuximab vedotin + CHP (cyclophosphamide, doxorubicin, and prednisone)</li> <li>CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)</li> <li>CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone)</li> <li>Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)</li> </ul>		
<p><u>Subcutaneous panniculitis-like T-cell lymphoma – examples of first-line therapy:</u></p> <ul style="list-style-type: none"> <li><u>Cyclosporine</u></li> <li><u>Romidepsin</u></li> <li><u>CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone)</u></li> <li><u>Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)</u></li> <li><u>ESHA (ifosfamide, carboplatin, etoposide) + platinum (cisplatin or oxaliplatin)</u></li> <li><u>ICE (ifosfamide, carboplatin, etoposide)</u></li> </ul>	Varies	Varies

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

None reported

Appendix D: PTCL Subtypes/Histologies\*

- PTCL, not otherwise specified
- Anaplastic large cell lymphoma
- Angioimmunoblastic T-cell lymphoma
- Enteropathy-associated T-cell lymphoma
- Monomorphic epitheliotropic intestinal T-cell lymphoma
- Nodal peripheral T-cell lymphoma with TFH phenotype
- Follicular T-cell lymphoma

\*PTCL is classified as a non-Hodgkin T-cell lymphoma. PTCL classification schemes are periodically advanced as new information becomes available; therefore, the above list is provided as general guidance. For additional information, see WHO's 2016 updated classification of hematological malignancies for a complete list of lymphoid neoplasms, including PTCL.

V. Dosage and Administration

**CLINICAL POLICY**

**Pralatrexate**



Indication	Dosing Regimen	Maximum Dose
PTCL	30 mg/m <sup>2</sup> IV once weekly for 6 weeks in 7-week cycles until progressive disease or unacceptable toxicity	30 mg/m <sup>2</sup> once weekly

**VI. Product Availability**

Single-dose vials: 20 mg/1 mL, 40 mg/2 mL

**VII. References**

1. Folutyn Prescribing Information. East Windsor, NJ: Acrotech Biopharma LLC; ~~September 2020~~ August 2024. Available at: <https://www.folutyn.com>. Accessed July ~~17, 2024~~ 14, 2025.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at nccn.org. Accessed ~~August 7, 2024~~ July 14, 2025.
3. National Comprehensive Cancer Network. T-Cell Lymphomas Version ~~4.2024~~ 2025. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/t-cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf). Accessed ~~August 7, 2024~~ July 14, 2025.
4. National Comprehensive Cancer Network. Primary Cutaneous Lymphomas Version 3.2025. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/primary\\_cutaneous.pdf](https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf). Accessed July 14, 2025.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9307	Injection, pralatrexate, 1 mg

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Converted corporate to local policy.	06.15.23	10.05.23
Annual review: no significant changes; references reviewed and updated.	04.22.24	07.10.24
Revised policy/criteria section to also include generic pralatrexate; for non-cutaneous T-cell lymphomas, added requirement that Folutyn be prescribed as a single agent per NCCN; removed “gamma delta” qualifier from hepatosplenic T-cell lymphoma as NCCN does not specify this; references reviewed and updated.	12.10.24	<u>03.17.25</u>
<u>Annual review: added NCCN off-label use for subcutaneous panniculitis-like T-cell lymphoma; for brand requests, added redirection to generic; extended initial approval duration from 6 to 12 months; references reviewed and updated.</u>	<u>11.20.25</u>	

Formatted Table

**Important Reminder**

## CLINICAL POLICY

### Pralatrexate



This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2025 Louisiana Healthcare Connections All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law

**CLINICAL POLICY**  
Pralatrexate



and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.